Sol­id tu­mor biotech’s poly­mer nanopar­ti­cle-drug con­ju­gate clears ear­ly-stage hur­dle, spark­ing PhII plans

Dan­tari’s drug con­ju­gate as­set has pro­duced pos­i­tive da­ta as both a monother­a­py and in com­bi­na­tion with a PARP in­hibitor in an ear­ly-stage breast can­cer tri­al …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER